While Canada has a corner on the cannabis stock market, the U.S. is beginning to produce its own hot stocks. This year the NASDAQ beauty to watch seems to be MariMed (OTC:MRMD). MariMed helps cultivation centers and dispensaries with everything from design to funding solutions.
Their site describes the services they provide as, “Helping build gold standard medical cannabis facilities and programs, one state at a time.” So though they don’t grow cannabis themselves, they do everything needed to help others do so in the best way possible.
Another thing that sets this company, and thus stock, apart is that it also helps to procure state licenses, which can be a hurdle for many. The application process is often so involved and complicated that potential dispensary owners and cultivators need the help of a professional. It just so happens that these professionals also provide turnkey solutions.
-
Related Story: California Carr Fire: When Cannabis Crops Go Up In Smoke
It’s a big deal to be the top performing pot stock for the first half of 2018, and that success could be in part that MariMed is so multifaceted while keeping a sort of cohesion. They sell infused edibles under their umbrella along with all of the services at the ground level of creating a successful cannabis business.
As MariMed continues to expand their reach “one state at a time” we’ll see if they can keep momentum. As any good trader knows, past performance isn’t a guarantee of future prosperity in the stock market.
From 2017 to 2022 the cannabis market is set to increase threefold to upwards of $22 billion. This bodes well for any cannabis stock worth its salt, but it’s not an end all be all of a statistic, investing in MariMed or any other pot stock has its own set of particular risks.
-
Related Story: You Want to Work In Weed? Here’s Some Advice
The biggest risk for any marijuana stock is cannabis’ Schedule I status, meaning that it’s completely illegal at the federal level and seen as a drug with no medical value and a high potential for abuse. Though the benefits of medical marijuana are by now beyond well documented, the U.S. government carries on with old, failed drug war remnants.
The other risk is that though they continue to expand, MariMed is in a lot of debt. And they continue to lose money. They’re paying down said debt, however, and while we can’t predict what the future holds for any of us, “MariMed continues on a solid trajectory of year over year growth that it has achieved each quarter since 2015,” according to MariMed CEO Robert Fireman.
